BioLife Solutions (BLFS)
(Real Time Quote from BATS)
$23.19 USD
+0.31 (1.36%)
Updated Aug 7, 2024 09:49 AM ET
4-Sell of 5 4
F Value C Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BLFS 23.19 +0.31(1.36%)
Will BLFS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BLFS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BLFS
Owens & Minor (OMI) Q2 Earnings and Revenues Surpass Estimates
ResMed (RMD) Beats Q4 Earnings and Revenue Estimates
BLFS: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes BioLife Solutions (BLFS) a Good Fit for 'Trend Investing'
BioLife (BLFS) Progresses in Cell & Gene Therapy With CryoCase
BioLife Solutions, Inc. (BLFS) Reports Q1 Loss, Tops Revenue Estimates
Other News for BLFS
Analysts Conflicted on These Healthcare Names: BioLife Solutions (BLFS), Arvinas Holding Company (ARVN) and Natera (NTRA)
BioLife Solutions to Report Second Quarter 2024 Financial Results and Business Update on August 8, 2024
BioLife Solutions price target raised by $6 at TD Cowen, here's why
BioLife Solutions: Strong Buy Rating on Robust Gross Margins and Positive Long-Term EBITDA Outlook
Insider Sale: Todd Berard Sells 10,000 Shares of BioLife Solutions Inc (BLFS)